SH2D1A, SH2 domain containing 1A, 4068

N. diseases: 160; N. variants: 8
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006413
Disease: Burkitt Lymphoma
Burkitt Lymphoma
0.080 GeneticVariation disease BEFREE Fatal Central Nervous System Lymphocytic Vasculitis after Treatment for Burkitt Lymphoma in a Patient with a SH2D1A Mutation. 30138256 2019
CUI: C0006413
Disease: Burkitt Lymphoma
Burkitt Lymphoma
0.080 AlteredExpression disease BEFREE Our results with BL derived cell lines suggest that the fate of the precursor cells is decided by the expression of the proapototic SAP and EBV infection. 20080127 2010
CUI: C0006413
Disease: Burkitt Lymphoma
Burkitt Lymphoma
0.080 Biomarker disease BEFREE To the genesis of Burkitt lymphoma: regulation of apoptosis by EBNA-1 and SAP may determine the fate of Ig-myc translocation carrying B lymphocytes. 19874894 2009
CUI: C0006413
Disease: Burkitt Lymphoma
Burkitt Lymphoma
0.080 AlteredExpression disease BEFREE Dok1 expression was down-regulated in all BL and XLP-LCL cell lines in comparison to the control cells. 16338067 2007
CUI: C0006413
Disease: Burkitt Lymphoma
Burkitt Lymphoma
0.080 Biomarker disease BEFREE Activation of endogenous wt p53 in BLs and lymphoblastoid cell lines led to the induction of SAP and this was inhibited by the specific p53 inhibitor pifithrin-alpha. 15378026 2004
CUI: C0006413
Disease: Burkitt Lymphoma
Burkitt Lymphoma
0.080 Biomarker disease BEFREE All the EBV-carrying Group III (immunoblastic) and the EBV-negative BL lines tested were SH2D1A-negative. 12115526 2002
CUI: C0006413
Disease: Burkitt Lymphoma
Burkitt Lymphoma
0.080 AlteredExpression disease BEFREE We studied SAP expression in several Burkitt lymphoma (BL) derived lines. 12008045 2002
CUI: C0006413
Disease: Burkitt Lymphoma
Burkitt Lymphoma
0.080 GeneticVariation disease BEFREE To study whether the clinical manifestation of XLP gene defects and/or polymorphisms extends beyond the classically recognized phenotype, we analyzed patients for the presence of SH2D1A gene alterations who presented with fatal or nonfatal, yet unusually severe or chronic EBV infections, and other possibly EBV-associated diseases, such as Hodgkin's lymphomas or nonendemic Burkitt's lymphomas and Burkitt-type leukemias. 12224001 2002